Advertisement

Topics

Latest AstraZeneca NewsRSS

02:18 EDT 23rd August 2017 | BioPortfolio

AstraZeneca ups its mRNA stake through €25m Ethris deal

AstraZeneca has entered a five-year collaboration to develop therapies for respiratory diseases based on Ethris’ messenger RNA (mRNA) technology.

AstraZeneca taps Ethris in RNA deal

The five-year deal focuses on discovery and development of respiratory treatments, adding to the big pharma's growing respiratory portfolio.

Finalists Announced for 2017 LogiPharma Supply Chain Awards

LONDON, August 22, 2017 /PRNewswire/ -- Industry awards celebrating projects and teams that have transformed supply chains in pharmaceutical companies. https://logipharmaawards.wbresearch.com/ LogiPharma announces 2017 Finalists for this year's LogiPharma Supply Chain Awards LogiPharma is delighted to announce this year's finalists at the inaugural LogiPharma Supply Chain Awards afte...

Perrigo prepping launch of Nexium 24HR equivalent following FDA OK

The company has reached a settlement of patent litigation with AstraZeneca, allowing for its store brand capsules to launch at the end of next month. read more

AstraZeneca Teams Up with German Biotech to Develop mRNA Therapy

AstraZeneca and its R&D arm MedImmune have partnered with Munich-based Ethris to use its mRNA technology to develop treatments for respiratory disease.  Ethris, located in the Munich biotech hub of Martinsried, has attracted the attention of AstraZeneca with its mRNA ... This awesome article AstraZeneca Teams Up with German Biotech to Develop mRNA Therapy appeared first on Labiotech.eu. Be ki...

Ironwood wins FDA approval for combo gout drug

The biotech expects the oral therapy to further grow its gout franchise, established last year with the acquisition of U.S. rights to Zurampic from AstraZeneca. 

Champions Oncology Announces Strategic Collaboration with AstraZeneca to Develop Unique Cohorts of Patient-Derived Xenograft (PDX) Models

HACKENSACK, N.J., Aug. 21, 2017 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced a strategic collaboration with AstraZeneca to develop novel cohorts of PDX models. These models will be used in AstraZeneca's oncology R&...

AstraZeneca, Ethris Collaborate to Develop mRNA-based Respiratory Disease Therapies

AstraZeneca and its biologics operation MedImmune negotiated a five year strategic research collaboration with mRNA therapeutics firm Ethris, focused on developing stabilized, non-immunogenic modified RNA therapies for respiratory diseases. The partnership will exploit Ethris’ proprietary Stabilized Non-Immunogenic mRNA (SNIM®RNA) technology, which engineers chemical modifications in RNA mo...

Ethris Enters Strategic Collaboration with AstraZeneca and MedImmune to Develop mRNA Therapies for Respiratory Diseases

Ethris GmbH, a leader in mRNA-based therapeutics with specific expertise in pulmonary disease, today announced a five-year strategic research collaboration with AstraZeneca and its global biologics research and development arm, MedImmune. The collaboration is focused on developing new stabilised non-immunogenic modified RNA therapies for respiratory diseas...

AstraZeneca PLC Jumps Deeper Into mRNA Drugs With Ethris Deal

  Life Sciences Jobs   ...

Ethris Enters Strategic Collaboration With AstraZeneca PLC And MedImmune To Develop mRNA Therapies For Respiratory Diseases

  Life Sciences Jobs   ...

FDA approves expanded use of AstraZeneca ovarian cancer drug

The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The agency also approved a new two-tablet regimen for the drug, regardless of whether patients test positive for BRCA genetic mutations associated wit...

AstraZeneca and MSD Expand Use of Oral Ovarian Cancer Drug

AstraZeneca and its partner MSD have announced that the FDA has granted approval to Lynparza as a treatment for several forms of recurrent cancer. Lynparza (olaparib) is now an oral treatment intended to reduce relapse in patients with recurrent ovarian, ... This awesome article AstraZeneca and MSD Expand Use of Oral Ovarian Cancer Drug appeared first on Labiotech.eu. Be kind and don't copy it wit...

Expanded label boosts AstraZeneca and Merck's Lynparza

Securing a broader indication for earlier treatment of ovarian cancer should help Lynparza fend off competition from rival PARP inhibitors.

Heads Up Tesaro: AstraZeneca PLC, Merck & Co.'s Ovarian Cancer Med Just Got Expanded Use From the FDA

  Life Sciences Jobs   ...

Heads Up Tesaro: AstraZeneca PLC, Merck & Co.'s Ovarian Cancer Drug Just Got Expanded Use From the FDA

  Life Sciences Jobs   ...

LYNPARZA® (olaparib) Receives Additional FDA Approval in the US for Ovarian Cancer

LYNPARZA’s new tablet formulation approved as maintenance treatment for women with recurrent ovarian cancer regardless of BRCA-mutation status LYNPARZA tablets also indicated in BRCA-mutated ovarian cancer beyond the third-line setting Newly-approved tablet formulation means reduced pill count compared to capsules Astr...

LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer

LYNPARZA’s New Tablet Formulation Approved as Maintenance Treatment for Women With Platinum-Sensitive Recurrent Ovarian Cancer Regardless of BRCA-Mutation Status LYNPARZA Tablets Also Indicated in BRCA-Mutated Ovarian Cancer Beyond the Third-Line Setting Newly-Approved Tablet Formulation Means Improved Patient Convenience Ast...

Constipation Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $2000

DelveInsight's, Constipation Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Constipation. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Constipation. This report provides information on the therapeutic development for Constipation, dealing with all the pipeline drug...

Astrazeneca Pharma India Ltd ASTRAZEN Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

SummaryAstraZeneca Pharma India Ltd AstraZeneca, a subsidiary of AstraZeneca Plc is a biopharmaceutical company that discovers, develops, and commercializes medicines. The company offers products in the therapeutic areas of cardiovascular and metabolic diseases, respiratory, maternal healthcare, oncology, infection, neuroscience, and gastrointestinal. Its cardiovascular and metabolic disease produ...

#jobs #lifescience MedImmune: Engineering Business Process Specialist

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: MedImmune: Engineering Business Process Specialist . Negotiable: MedImmune: Title: Engineering Business Process Specialist Salary: CompetitiveLocation: Liverpool, UK MedImmune is the global biologics research and development arm of AstraZeneca. … Continue reading →...

AstraZeneca Plc AZN Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25072017] Prices from USD $250

SummaryAstraZeneca plc AstraZeneca is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease CVMD; and cancer, besides autoimmune, infection and neurological diseases. The company's product portfolio includes biologics, prescription pharmaceuticals an...

AstraZeneca PLC: Buy The Dip?

  Life Sciences Jobs   ...

Acalabrutinib Granted Breakthrough Therapy Designation by US FDA for the Treatment of Patients with Mantle Cell Lymphoma

AstraZeneca and its hematology research and development center of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is an investigati...

Pharma Giant AstraZeneca PLC Scores Another FDA Breakthrough

  Life Sciences Jobs   ...

Quick Search
Advertisement
 

review and buy AstraZeneca market research data and corporate reports here